Abbott (NYSE:ABT) announced today that it received FDA clearance for its FreeStyle Libre 2 iOS application for use with compatible iPhones.
The Abbott Park, Ill.-based company designed the new FreeStyle Libre 2 app to enable users to get glucose readings directly on their iPhones without the use of a reader, allowing caregivers to remotely monitor glucose readings and get real-time alarms through the LibreLinkUp app.
FDA clearance allows use of the new app for adults and children four years of age and older with diabetes, according to a news release. The app offers personalized, up-to-the-minute glucose data for those with diabetes who are using FreeStyle Libre 2 glucose sensors.
By scanning their sensor with the app, users can obtain their current glucose reading and trend arrow to help determine how food, exercise and more impact their diabetes management.
Abbott said the FreeStyle Libre 2 iOS app will be available to download on the App Store in the U.S. soon.
“The demands of living with diabetes can be overwhelming, and there’s a critical need to improve the way people with diabetes manage their condition – easily, affordably, accurately – and in a way that seamlessly fits into their everyday lives,” Abbott diabetes care SVP Jared Watkin said in the release. “The FreeStyle Libre 2 iOS app streamlines how people manage their diabetes on their iPhones – empowering users with the information they need 24/7 while improving their health on the go.”
